Serum PSA and cure perspective for prostate cancer in males with nonpalpable tumor

International Braz J Urol

Volumn 31, Issue 5, 2005, Pages 437-444

  Dall'Oglio, Marcos F ^a,b   Crippa, Alexandre ^a   Passerotti, Carlo C ^a   Nesrallah, Luciano J ^a   Leite, Katia R ^a   Srougi, Miguel ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Rua Barata Ribeiro   (Brazil)

Author keywords

Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Treatment outcome

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER STAGING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 28044469044     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382005000500004     Document Type: Article

References (20)

1. Sirovich BE, Woloshin S, Schwartz LM: Screening men for prostate and colon cancer: are priorities in order? J Gen Intern Med. 2002; 17 (Suppl. 1): 212.
2. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR: The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22: 2141-9.
3. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-46. Erratum in: N Engl J Med. 2004; 351: 1470.
4. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993; 71 (Suppl 3): 933-8.
5. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, et al.: Prostate-specific antigen cut-off of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology. 2002; 60: 469-73; discussion 473-4.
6. Stephenson RA: Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002; 29: 173-81.
7. Hernandez J, Thompson IM: Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004; 101: 894-904.
8. Beahrs OH, Henson DE, Hutter RVP: American Joint Committee on Cancer Manual for Staging Cancer. 4th Ed, Philadelphia, JB Lippincott. 1992.
9. Gleason DF: Histologic Grading and Staging of Prostatic Carcinoma. In: Tannenbaum M (ed.), Urologic Pathology. Philadelphia, Lea & Febiger. 1977; pp. 171-87.
10. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H: The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003; 170: 1872-6.
11. Carter HB: Prostate cancers in men with low PSA levels - must we find them? N Engl J Med. 2004; 350: 2292-4.
12. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al.: Cancer statistics, 2004. CA Cancer J Clin. 2004; 54: 8-29.
13. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al.: High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994; 8: 439-43.
14. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al.: Natural history of early, localized prostate cancer. JAMA. 2004; 291: 2713-9.
15. Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280: 975-80.
16. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, et al.: Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003; 21: 4001-8.
17. Whitmore WF Jr, Warner JA, Thompson IM Jr: Expectant management of localized prostatic cancer. Cancer. 1991; 67: 1091-6.
18. Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA. 1994; 271: 368-74.
19. Carter HB, Walsh PC, Landis P, Epstein JI: Expectant management of non-palpable prostate cancer with curative intent: preliminary results. J Urol. 2002; 167: 1231-4.
20. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE: Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996; 88: 166-73.